Economic burden of alcohol abuse

Czech version

Authors: I. Šmídová
Authors‘ workplace: Přednostka:prof. MUDr. Zuzana Derflerová Brázdová, DrSc. ; Lékařská fakulta ; Ústav preventivního lékařství ; Masarykova univerzita, Brno
Published in: Prakt. Lék. 2012; 92(1): 23-30
Category: Reviews

Overview

This article analyses one contemporary severe socioeconomic issue – alcohol abuse. It shows data for Czech and European populations, and reveals that the economic burden related directly, and indirectly, to the treatment of illnesses caused by excessive alcohol consumption is fairly significant. Tax losses caused by

premature death due to alcohol abuse,
deaths in productive age caused by alcohol,
tumours evolved from dependency on alcohol, where there is evidence of causality, and
other influences were also taken into account when estimating societal burden.

Evaluation is based on Alcohol Attributable Fraction (AAF) described in (2). Indeterminable costs remain due to low patient compliance (therapy neglect, etc.), which cause more severe course of the disease and thereby higher costs. Data from the year 2006 was chosen because the results are reasonably up-to-date and it had the most complete statistical reports.

Key words:
alcohol abuse, societal burden, mortality, morbidity.

Sources

1. Burcin, B., Kučera, T. Strukturální změny úmrtnosti v českých zemích a na Slovensku mezi roky 1991 a 2006. Demografie, 2008, 50,s. 172-188.

2.Cipriani, F., Landucci, L.Alcohol-related mortality and morbidity data sources and a tentative analysis of alcohol-related mortality in Europe. In Bloomfield, K. et al. Alcohol consumption and alcohol problems among women in European countries. Project Final Report. Berlin:Free University of Berlin, Institute for Medical Informatics, Biostatistics & Epidemiology,1999, p. 205-234.

3.Schäfer, G., Baryn, M., Fritz, M. et al. (Eds). Europe in figures. EurostatYearbook 2006-7. Luxembourg : Office for Official Publications of the European Communities; 2008.

4.Ferlay, J., Bray, F., Pisani, P., Parkin, D.M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, Version 2.0. IARC CancerBase No. 5. Lyon: IARC Press, 2004.

5. Gold, M.R., Siegel, J.E., Russel, L.B.Cost-effectiveness in health and medicine. New York: Oxford University Press 1996.

6. Hrach, K., Mihla, J. Metodické přístupy ke konstrukci souhrnných ukazatelů. Statistika 2006, 42,s. 398-418.

7. Kabelka, L., Vorlíček, J. Paliativní medicína pro praxi. Praha:Galén, 2007.

8.Mauskopf J.A., Earnshaw, S., Mullins, C.D. Budget impact analysis: review of the state of the art. Expert Rev. Pharmacoecon Outcomes Res. 2005, 5,p. 65-79.

9.Mauskopf, J.A., Sullivan, S.D., Annemans, L. et al. Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on good research practices – budget impact analysis.ValueHealth 2007, 10, p. 336-347.

10. Mrozek, J.R., Tailor, L.O.What determines the value of life? A metaanalyses. J. Policy Anal. Manage 2002, 21, p .253-270.

11.Polder, J.J., Meerding, W.J., Bonneux L. et al. A cross-national perspective on costofillness. Eur. J. Health Econom. 2005, 50, p. 223-232.

12.Rice, D.P., Kolman S., Miller, L.S., et al. The economic costs of alcohol and drug abuse and mental illness. Bethesda: National Institute on Drug Abuse, 1990.

13. Segel, J.E. Cost-of-illness studies-a primer. RTI-UNC Center of Excellence in a Health Promotion Economics, 2006 [on-line]. Dostupný na http://rti.org/pubs/COI_Primer.pdf.

14.Trueman, P., Drummond, M., Hutton, J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19,p. 609-621.

15. ÚZIS ČR, NOR ČR. Novotvary 2006. Praha: ÚZIS ČR, 2009.

16.ÚZIS ČR. Lůžková péče 2006. Praha: ÚZIS ČR, 2007.

17.ÚZIS ČR. Ukončené případy pracovní neschopnosti pro nemoc a úraz 2006. Praha: ÚZIS ČR, 2007.

18.ÚZIS ČR. Zemřelí 2006. Praha: ÚZIS ČR, 2007.

19. ÚZIS ČR. Ekonomické informace ve zdravotnictví 2006. Praha: ÚZIS ČR, 2008.

20. Vlček, J., a kol. Farmakoepidemiologie – farmakoekonomika – farmakoinformatika.Praha: Panax, 1999.

Labels

General practitioner for children and adolescents General practitioner for adults

Basics of social cognitive and affective neuroscience; XIII. Creativity

Strategy of antiaggregation treatment after percutaneous coronary interventions

Potentially inappropriate (risky) drugs at geriatric patients Expert consensus for the Czech Republic 2012

Problems of colorectal carcinoma in primary care

Current role of endoscopic ultrasound investigation in the diagnosis of pancreatic diseases – our experiences

Risk factors for cardiovascular diseases in regular yoga practitioners in comparison with general population

A survey of motivational factors in non-medical health professionals

Psychoactive substances abuse and diabetes mellitus

Article was published in

General Practitioner

2012 Issue 1